Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta‐analysis

Autor: Fei Zhao, Shuilian Zhu, Guo Tian, Cong Sun, Xinlin Chen, Yu‐Mei Wang, Fengbin Liu, Yi-Ming Chen, Xiao‐Bing Lin, Xiaofei Yang, Zheng Chen, Yunpeng Gao, Tian‐Ge Yang
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
Genotype
gene polymorphism
Colorectal cancer
colorectal cancer
Single-nucleotide polymorphism
Subgroup analysis
Review Article
Polymorphism
Single Nucleotide
03 medical and health sciences
0302 clinical medicine
Gene Frequency
Internal medicine
Drug Discovery
Odds Ratio
Genetics
medicine
Humans
Genetic Predisposition to Disease
Prospective cohort study
Molecular Biology
Alleles
Methylenetetrahydrofolate Reductase (NADPH2)
Genetics (clinical)
biology
business.industry
Prognosis
medicine.disease
methylenetetrahydrofolate reductase
digestive system diseases
Confidence interval
030104 developmental biology
meta‐analysis
030220 oncology & carcinogenesis
Methylenetetrahydrofolate reductase
Meta-analysis
biology.protein
Molecular Medicine
Gene polymorphism
Colorectal Neoplasms
business
Zdroj: The Journal of Gene Medicine
ISSN: 1521-2254
1099-498X
Popis: Background The present study focused on understanding the prognostic value of the methylenetetrahydrofolate reductase (MTHFR) single nucleotide polymorphisms rs1801133 (C667T) and rs1801131 (A1298C) in patients with colorectal cancer (CRC). Methods A systematic literature search was conducted in March 2016. Databases, including Medline, EMBASE, Cochrane and Chinese databases (including CNKI, Wanfang and VIP), were searched to identify the relevant articles describing MTHFR polymorphisms in patients with CRC. Data regarding overall survival (OS), progression‐free survival (PFS) and disease‐free survival (DFS) were collected and analysed. Results Twenty‐four studies with 5423 patients with CRC were included. Significant differences in OS, PFS and DFS were not observed among the different comparisons of patients carrying different alleles of the MTHFR rs1801133 polymorphism (including TT versus CC, TT versus CT + CC, CT + TT versus CC and CT versus CC). Compared with patients with the rs1801131 CA + AA genotypes, patients with the CC genotype had a shorter OS (hazard ratio = 1.85; 95% confidence interval = 1.30–2.65) and DFS (hazard ratio = 2.16; 95% confidence interval= 1.19–3.93). Significant differences in OS, PFS and DFS were not observed among the other patient groups (including CC versus AA, CC + CA versus AA and CA versus AA). Subgroup analysis of rs1801133 and rs1801131 showed that patients with CRC from Asian regions and Western regions demonstrated similar results. Conclusions The MTHFR rs1801133 polymorphism was not associated with the prognosis of patients with CRC; however, rs1801131 may be associated with the prognosis of patients with CRC. Well‐designed prospective studies are necessary to obtain a better understanding of the prognostic value of rs1801133 and rs1801131.
Databáze: OpenAIRE
Externí odkaz: